VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ESMO 2019 | No clear evidence for benefit with addition of Rova-T to chemo for extensive SCLC

Ross Camidge, MD, PhD, University of Colorado, Denver, CO, discusses the phase I study evaluating rovalpituzumab tesirine (ROVA-T) in the frontline treatment of patients with extensive-stage small-cell lung cancer (NCT02819999). This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter